文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

膀胱癌免疫治疗中靶向代谢重编程:一种精准医学方法。

Targeting Metabolic Reprogramming in Bladder Cancer Immunotherapy: A Precision Medicine Approach.

作者信息

Liu Fuyang, Li Kai, Zhu Qingyi

机构信息

Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China.

出版信息

Biomedicines. 2025 May 9;13(5):1145. doi: 10.3390/biomedicines13051145.


DOI:10.3390/biomedicines13051145
PMID:40426972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12108893/
Abstract

Bladder cancer, as a highly heterogeneous malignant tumor of the urinary system, is significantly affected by tumor metabolic reprogramming in its response to immunotherapy. This review systematically elaborates on the molecular mechanisms of abnormal glucose and lipid metabolism in the bladder cancer microenvironment and immune escape, and discusses precision treatment strategies based on metabolic regulation. In the future, it will be necessary to combine spatiotemporal omics and artificial intelligence technologies to construct a multi-target intervention system for the metabolic-immune interaction network, promoting a paradigm shift in precision treatment for bladder cancer.

摘要

膀胱癌作为泌尿系统一种高度异质性的恶性肿瘤,在其对免疫治疗的反应中受到肿瘤代谢重编程的显著影响。本文综述系统阐述了膀胱癌微环境中糖脂代谢异常及免疫逃逸的分子机制,并探讨了基于代谢调控的精准治疗策略。未来,有必要结合时空组学和人工智能技术,构建代谢-免疫相互作用网络的多靶点干预体系,推动膀胱癌精准治疗的模式转变。

相似文献

[1]
Targeting Metabolic Reprogramming in Bladder Cancer Immunotherapy: A Precision Medicine Approach.

Biomedicines. 2025-5-9

[2]
Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy.

Front Immunol. 2025-4-28

[3]
The role of lipid metabolic reprogramming in tumor microenvironment.

Theranostics. 2023

[4]
Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects.

Front Immunol. 2025-1-24

[5]
The role of metabolic reprogramming in immune escape of triple-negative breast cancer.

Front Immunol. 2024

[6]
Emerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer.

Int Immunopharmacol. 2025-1-10

[7]
Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications.

Cancer Lett. 2024-8-10

[8]
Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy.

Front Immunol. 2024

[9]
The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma.

Int J Mol Sci. 2024-5-21

[10]
Unraveling the immune evasion mechanisms in the tumor microenvironment of head and neck squamous cell carcinoma.

Front Immunol. 2025-5-14

引用本文的文献

[1]
The impact of METTL3 on bladder cancer through mA modification: a potential therapeutic target and prognostic biomarker.

Front Oncol. 2025-7-3

本文引用的文献

[1]
Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer.

Curr Oncol Rep. 2025-3

[2]
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers.

Int J Mol Sci. 2025-1-31

[3]
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes.

Hum Vaccin Immunother. 2025-12

[4]
CircZNF609 inhibited bladder cancer immunotherapy sensitivity via enhancing fatty acid uptake through IGF2BP2/CD36 pathway.

Int Immunopharmacol. 2024-8-20

[5]
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2024

[6]
Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer.

J Transl Med. 2024-1-13

[7]
Acyl-coenzyme A: cholesterol acyltransferase inhibitor avasimibe suppresses tumorigenesis and induces G1-phase cell-cycle arrest by activating PPARγ signaling pathway in bladder cancer.

J Cancer. 2024-1-1

[8]
Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance.

Nat Commun. 2024-1-2

[9]
Lipidomics Profiling Reveals Differential Alterations after FAS Inhibition in 3D Colon Cancer Cell Culture Models.

J Proteome Res. 2024-8-2

[10]
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.

Eur Urol. 2024-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索